Some Q3 recovery (vs. Q2); full-year guidance reiterated
16/10/20 -"After a disappointing Q2 (-4% CER sales growth), Roche had some respite in Q3 (+1%) – though below expectations, largely driven by diagnostics due to the strong demand for COVID-19 tests. While the ..."
Pages
70
Language
English
Published on
16/10/20
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated